
PROSTATE cancer patients with weeks or months left to live could survive longer after undergoing immunotherapy treatment, a major trial has shown. More than a third of men with a very advanced form of the cancer were still alive, and one in 10 had not seen the cancer grow, after a year on the drug pembrolizumab, the study found.
0 comments:
Post a Comment
Note: Only a member of this blog may post a comment.